AI Article Synopsis
- Professional guidelines suggest treating obesity as a chronic disease with lifestyle changes and medication, but antiobesity drugs are rarely prescribed in practice.
- The recent FDA approval of semaglutide 2.4 mg for obesity, along with new developments in diabetes and weight loss medications, shows the potential benefits of using drugs to enhance weight loss efforts.
- This Expert Endocrine Consult evaluates the changing role of antiobesity medications in healthcare and proposes a framework for their effective use.
Article Abstract
Despite professional society guidelines recommending that obesity be treated as a chronic disease by emphasizing the use of lifestyle modification in conjunction with pharmacotherapy, antiobesity medications are uncommonly prescribed in most clinical practices. The recent Food and Drug Administration approval of semaglutide 2.4 mg weekly to treat obesity-as well as other forthcoming advancements in diabetes and antiobesity medications-highlights the potential of pharmacotherapy to significantly augment weight loss efforts. In this Expert Endocrine Consult, we review the evolving role of antiobesity pharmacotherapy in clinical practice and suggest a framework for the use of these medications.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847544 | PMC |
| http://dx.doi.org/10.1210/jendso/bvac195 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!